$MED
MEDIFAST INC

2013 Q4 Form 10-Q Financial Statement

#000114420413060506 Filed on November 12, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q4
Revenue $70.30M $86.48M $83.20M
YoY Change -15.5% -4.93% 19.54%
Cost Of Revenue $18.30M $21.63M $20.40M
YoY Change -10.29% -4.44% 18.6%
Gross Profit $51.90M $64.85M $62.80M
YoY Change -17.36% -5.1% 20.08%
Gross Profit Margin 73.83% 74.99% 75.48%
Selling, General & Admin $41.90M $57.50M $59.00M
YoY Change -28.98% -3.2% 16.37%
% of Gross Profit 80.73% 88.67% 93.95%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $2.692M $200.0K
YoY Change -100.0% -9.27% -92.0%
% of Gross Profit 0.0% 4.15% 0.32%
Operating Expenses $41.90M $57.50M $59.20M
YoY Change -29.22% -3.2% 16.77%
Operating Profit $10.00M $7.349M $3.600M
YoY Change 177.78% -17.69% 125.0%
Interest Expense $200.0K $167.0K $100.0K
YoY Change 100.0% 160.94% -200.0%
% of Operating Profit 2.0% 2.27% 2.78%
Other Income/Expense, Net -$500.0K $529.0K $0.00
YoY Change 937.25% -100.0%
Pretax Income $9.800M $7.878M $3.600M
YoY Change 172.22% -12.26% 140.0%
Income Tax $2.600M $2.205M $1.800M
% Of Pretax Income 26.53% 27.99% 50.0%
Net Earnings $5.300M $5.673M $1.900M
YoY Change 178.95% -21.3% 58.33%
Net Earnings / Revenue 7.54% 6.56% 2.28%
Basic Earnings Per Share $0.41
Diluted Earnings Per Share $389.7K $0.41 $137.7K
COMMON SHARES
Basic Shares Outstanding 13.88M shares 13.88M shares
Diluted Shares Outstanding 13.90M shares

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $104.2M $130.0M $99.93M
YoY Change 4.26% 106.66% 195.65%
Cash & Equivalents $36.38M $47.98M $39.94M
Short-Term Investments $67.80M $82.01M $59.99M
Other Short-Term Assets $5.600M $2.900M $4.800M
YoY Change 16.67% -6.45% 41.18%
Inventory $17.54M $17.45M $20.80M
Prepaid Expenses
Receivables $942.0K $1.932M $2.148M
Other Receivables $0.00 $2.600M $900.0K
Total Short-Term Assets $91.95M $106.9M $88.58M
YoY Change 3.81% 21.98% 38.43%
LONG-TERM ASSETS
Property, Plant & Equipment $34.48M $41.14M $40.11M
YoY Change -14.04% 5.75% 3.24%
Goodwill
YoY Change
Intangibles $0.00 $49.00K $428.0K
YoY Change -100.0% -57.33%
Long-Term Investments
YoY Change
Other Assets $231.0K $356.0K $1.139M
YoY Change -79.72% -70.33% -37.55%
Total Long-Term Assets $40.70M $41.54M $41.68M
YoY Change -2.35% 2.06% -0.01%
TOTAL ASSETS
Total Short-Term Assets $91.95M $106.9M $88.58M
Total Long-Term Assets $40.70M $41.54M $41.68M
Total Assets $132.7M $148.4M $130.3M
YoY Change 1.84% 15.66% 23.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.00M $30.30M $28.20M
YoY Change -57.45% 3.06% 50.0%
Accrued Expenses $4.800M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $200.0K $225.0K
YoY Change -100.0% -66.67% -83.93%
Total Short-Term Liabilities $27.10M $30.56M $28.75M
YoY Change -5.73% 1.86% 41.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $3.113M
YoY Change -100.0% -100.0% -6.71%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $3.113M
YoY Change -100.0% -100.0% -6.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.10M $30.56M $28.75M
Total Long-Term Liabilities $0.00 $0.00 $3.113M
Total Liabilities $34.23M $37.06M $39.47M
YoY Change -13.25% -9.83% 22.32%
SHAREHOLDERS EQUITY
Retained Earnings $97.70M $95.21M $76.53M
YoY Change 27.66% 26.17%
Common Stock $13.00K $16.00K $16.00K
YoY Change -18.75% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $26.51M $26.51M
YoY Change -100.0% 11.64%
Treasury Stock Shares 0.000 shares 1.609M shares 1.609M shares
Shareholders Equity $98.42M $111.3M $90.79M
YoY Change
Total Liabilities & Shareholders Equity $132.7M $148.4M $130.3M
YoY Change 1.84% 15.66% 23.27%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q4
OPERATING ACTIVITIES
Net Income $5.300M $5.673M $1.900M
YoY Change 178.95% -21.3% 58.33%
Depreciation, Depletion And Amortization $0.00 $2.692M $200.0K
YoY Change -100.0% -9.27% -92.0%
Cash From Operating Activities $8.300M $6.400M $600.0K
YoY Change 1283.33% -22.89% -60.0%
INVESTING ACTIVITIES
Capital Expenditures -$2.800M -$3.000M -$700.0K
YoY Change 300.0% 42.86% -84.78%
Acquisitions
YoY Change
Other Investing Activities $3.000M $100.0K -$3.800M
YoY Change -178.95% 0.0% 375.0%
Cash From Investing Activities $200.0K -$2.900M -$4.600M
YoY Change -104.35% 45.0% -14.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -20.10M 200.0K 600.0K
YoY Change -3450.0% -300.0%
NET CHANGE
Cash From Operating Activities 8.300M 6.400M 600.0K
Cash From Investing Activities 200.0K -2.900M -4.600M
Cash From Financing Activities -20.10M 200.0K 600.0K
Net Change In Cash -11.60M 3.700M -3.400M
YoY Change 241.18% -41.27% -19.05%
FREE CASH FLOW
Cash From Operating Activities $8.300M $6.400M $600.0K
Capital Expenditures -$2.800M -$3.000M -$700.0K
Free Cash Flow $11.10M $9.400M $1.300M
YoY Change 753.85% -9.62% -78.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
4000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
20804000 USD
CY2013Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
30338000 USD
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
28221000 USD
CY2013Q3 us-gaap Liabilities
Liabilities
37058000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39937000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
39465000 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
106856000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
88575000 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41135000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40109000 USD
CY2012Q4 us-gaap Assets
Assets
130251000 USD
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42285000 USD
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
332000 USD
us-gaap Gross Profit
GrossProfit
205231000 USD
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
59408000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
183624000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
7349000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2148000 USD
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
20057000 USD
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1932000 USD
CY2013Q3 us-gaap Inventory Net
InventoryNet
17451000 USD
CY2013Q3 us-gaap Short Term Investments
ShortTermInvestments
34028000 USD
CY2013Q3 us-gaap Prepaid Taxes
PrepaidTaxes
2555000 USD
CY2012Q4 us-gaap Prepaid Taxes
PrepaidTaxes
873000 USD
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2035000 USD
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
165000 USD
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
304000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
34093000 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
7416000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
21576000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7435000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47980000 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
356000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1139000 USD
CY2013Q3 us-gaap Assets
Assets
148396000 USD
CY2013Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
530000 USD
CY2012Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
696000 USD
CY2013Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
5970000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6907000 USD
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
925000 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
148396000 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
111338000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
90786000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130251000 USD
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
16000 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q3 us-gaap Treasury Stock Value
TreasuryStockValue
26508000 USD
CY2012Q4 us-gaap Treasury Stock Value
TreasuryStockValue
26508000 USD
CY2012Q4 med Allowance For Doubtful Accounts Receivable And Sales Returns Current
AllowanceForDoubtfulAccountsReceivableAndSalesReturnsCurrent
542000 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
16000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40191000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
553000 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
95213000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
76534000 USD
CY2013Q3 med Allowance For Doubtful Accounts Receivable And Sales Returns Current
AllowanceForDoubtfulAccountsReceivableAndSalesReturnsCurrent
731000 USD
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15542118 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13884293 shares
CY2012Q3 us-gaap Revenues
Revenues
90968000 USD
us-gaap Revenues
Revenues
279595000 USD
CY2013Q3 us-gaap Cost Of Revenue
CostOfRevenue
21627000 USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15525955 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13767380 shares
CY2013Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
1608908 shares
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1608908 shares
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3296000 USD
CY2013Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
875000 USD
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1460000 USD
CY2013Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
49000 USD
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
428000 USD
CY2013Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
220000 USD
CY2012Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
528000 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30558000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28749000 USD
CY2013Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3113000 USD
CY2013Q3 us-gaap Revenues
Revenues
86480000 USD
us-gaap Revenues
Revenues
273464000 USD
us-gaap Cost Of Revenue
CostOfRevenue
69403000 USD
us-gaap Cost Of Revenue
CostOfRevenue
68233000 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
64853000 USD
CY2012Q3 us-gaap Gross Profit
GrossProfit
68336000 USD
us-gaap Gross Profit
GrossProfit
210192000 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
57504000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
185568000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
8928000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
26568000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
19663000 USD
CY2013Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
167000 USD
CY2012Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
64000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
317000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
226000 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
362000 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
581000 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
529000 USD
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
51000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
898000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1151000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
7878000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
8979000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
27466000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
20814000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2205000 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1771000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7097000 USD
CY2012Q3 us-gaap Cost Of Revenue
CostOfRevenue
22632000 USD
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.34
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13884293 shares
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
292000 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
32000 USD
CY2012Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
1000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
217000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
91000 USD
CY2013Q3 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
272000 USD
CY2012Q3 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
164000 USD
us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-221000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-221000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
201000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5945000 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7372000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
18458000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
14212000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7912000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8219000 USD
us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
201000 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
272000 USD
CY2012Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
164000 USD
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
337000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1772000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1816000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-47000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-440000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-85000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-59000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-216000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1255000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3353000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1690000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1261000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8787000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6803000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
5673000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
7208000 USD
us-gaap Net Income Loss
NetIncomeLoss
18679000 USD
us-gaap Net Income Loss
NetIncomeLoss
14011000 USD
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.02
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.02
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13705188 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13852155 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13709702 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13903412 shares
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13804212 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13955217 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13766013 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
19000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-764000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-219000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2117000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10603000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-1682000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
4828000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
39727000 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
7140000 USD
CY2012 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
942000 USD
CY2012 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
-56000 USD
CY2012 us-gaap Indefinitelived Intangible Assets Acquired
IndefinitelivedIntangibleAssetsAcquired
2672000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2244000 USD
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
118000 USD
CY2012Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
152000 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5685000 USD
CY2013Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
82008000 USD
CY2013Q3 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
34028000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6802000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8644000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22804000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3587000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1297000 USD
CY2013Q3 us-gaap Retail Related Inventory
RetailRelatedInventory
730000 USD
CY2012Q4 us-gaap Retail Related Inventory
RetailRelatedInventory
653000 USD
CY2013Q3 med Inventory Non Food Finished Goods
InventoryNonFoodFinishedGoods
796000 USD
CY2012Q4 med Inventory Non Food Finished Goods
InventoryNonFoodFinishedGoods
961000 USD
CY2013Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10936000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
13857000 USD
CY2013Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
246000 USD
CY2012Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
352000 USD
us-gaap Indefinitelived Intangible Assets Acquired
IndefinitelivedIntangibleAssetsAcquired
2672000 USD
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
58997000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
19000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
13000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3246000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3481000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8043000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
29149000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14262000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43411000 USD
us-gaap Interest Paid
InterestPaid
49000 USD
us-gaap Interest Paid
InterestPaid
93000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
10143000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
2249000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
322000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
567000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2764000 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
104000 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
CY2013Q3 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
224000 USD
CY2012Q3 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
104000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1772000 USD
us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
322000 USD
CY2013Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
5235000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
379000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
411000 USD
CY2013Q3 med Effect Of Dilutive Common Stock Equivalents
EffectOfDilutiveCommonStockEquivalents
19119 USD
CY2012Q3 med Effect Of Dilutive Common Stock Equivalents
EffectOfDilutiveCommonStockEquivalents
99024 USD
med Effect Of Dilutive Common Stock Equivalents
EffectOfDilutiveCommonStockEquivalents
103062 USD
med Effect Of Dilutive Common Stock Equivalents
EffectOfDilutiveCommonStockEquivalents
56311 USD
CY2013Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
81401000 USD
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
975000 USD
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
-475000 USD
CY2013Q3 us-gaap Interest Receivable
InterestReceivable
107000 USD
CY2012Q4 us-gaap Interest Receivable
InterestReceivable
111000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
59994000 USD
CY2012Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
20057000 USD
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13884293 shares
dei Entity Registrant Name
EntityRegistrantName
MEDIFAST INC
dei Entity Central Index Key
EntityCentralIndexKey
0000910329
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
MED
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div>1.</div> </td> <td style="TEXT-ALIGN: justify"> <div>Basis of Presentation</div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 13.5pt; TEXT-INDENT: -13.5pt"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> The condensed unaudited interim consolidated financial statements included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q and do not contain information included in the Company&#8217;s annual statements and notes. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> The results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the year ending December 31, 2013 or any other portions thereof. Certain information in footnote disclosures normally included in annual financial statements has been condensed or omitted for the interim periods presented in accordance with the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim consolidated financial statements.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> These financial statements do not contain all of the information and footnotes required by generally accepted accounting principles for complete financial statements. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> The consolidated balance sheet as of December 31, 2012 is derived from the audited financial statements included in the Company&#8217;s Annual Report in Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2012 (the 2012 form 10-K), which should be read in conjunction with these consolidated financial statements.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
149667 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
314706 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
151883 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
312490 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
8.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
25.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
13.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
22.95
us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
270000000 USD
CY2012Q3 med Payments To Civil Penalty
PaymentsToCivilPenalty
3700000 USD
CY2013Q3 med Selling General And Administrative Expenses Excluding Depreciation Depletion And Amortization
SellingGeneralAndAdministrativeExpensesExcludingDepreciationDepletionAndAmortization
54812000 USD
CY2013Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2692000 USD
CY2012Q3 med Selling General And Administrative Expenses Excluding Depreciation Depletion And Amortization
SellingGeneralAndAdministrativeExpensesExcludingDepreciationDepletionAndAmortization
56441000 USD
CY2012Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2967000 USD
CY2012Q3 us-gaap Assets
Assets
128300000 USD
med Selling General And Administrative Expenses Excluding Depreciation Depletion And Amortization
SellingGeneralAndAdministrativeExpensesExcludingDepreciationDepletionAndAmortization
175712000 USD
med Selling General And Administrative Expenses Excluding Depreciation Depletion And Amortization
SellingGeneralAndAdministrativeExpensesExcludingDepreciationDepletionAndAmortization
177349000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2623000 USD

Files In Submission

Name View Source Status
0001144204-13-060506-index-headers.html Edgar Link pending
0001144204-13-060506-index.html Edgar Link pending
0001144204-13-060506.txt Edgar Link pending
0001144204-13-060506-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
med-20130930.xml Edgar Link completed
med-20130930.xsd Edgar Link pending
med-20130930_cal.xml Edgar Link unprocessable
med-20130930_def.xml Edgar Link unprocessable
med-20130930_lab.xml Edgar Link unprocessable
med-20130930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v358216_10q.htm Edgar Link pending
v358216_ex31-1.htm Edgar Link pending
v358216_ex31-2.htm Edgar Link pending
v358216_ex32-1.htm Edgar Link pending